New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.
ÌÇÐÄ´«Ã½
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia. EJHaem Mannis, G. N., Abboud, C. N., Daver, N. G., Murthy, G. S., Wang, E. S., Bradley, T. J., Yaghmour, G., Vachhani, P., Balasubramanian, S. K., Chua, C. C., Fong, C. Y., Asch, A. S., Dong, M., Li, S., Bagheri, T., Doshi, P., Vyas, P., Malki, M. M. 2025; 6 (3): e70051Abstract
This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML.Endpoints included complete remission rate (CRR), overall response rate (ORR), overall survival (OS) and safety.Eighteen and 36 patients were enrolled into the unfit and R/R AML arms, respectively. CRR was 38.9% and 25.0%, ORR was 66.7% and 38.9%, and median OS was 15.3 and 10.5 months in the unfit AML and R/R AML arms, respectively. No dose-limiting toxicities or magrolimab-related deaths occurred.Magrolimab was safely combined with existing AML therapies with no new safety signals.This trail was registered at www.clinicaltrials.gov as NCT04778410.
View details for
View details for
View details for